ES3055488T3 - Tegavivint for use in the treatment of pulmonary fibrosis - Google Patents

Tegavivint for use in the treatment of pulmonary fibrosis

Info

Publication number
ES3055488T3
ES3055488T3 ES18809912T ES18809912T ES3055488T3 ES 3055488 T3 ES3055488 T3 ES 3055488T3 ES 18809912 T ES18809912 T ES 18809912T ES 18809912 T ES18809912 T ES 18809912T ES 3055488 T3 ES3055488 T3 ES 3055488T3
Authority
ES
Spain
Prior art keywords
group
tegavivint
compound
cells
pulmonary fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18809912T
Other languages
English (en)
Spanish (es)
Inventor
Ruolan Han
Jon Northrup
Srinivas Kasibhatla
Stephen Horrigan
Jeff Larson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iterion Therapeutics Inc
Original Assignee
Iterion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iterion Therapeutics Inc filed Critical Iterion Therapeutics Inc
Application granted granted Critical
Publication of ES3055488T3 publication Critical patent/ES3055488T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES18809912T 2017-06-02 2018-06-01 Tegavivint for use in the treatment of pulmonary fibrosis Active ES3055488T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762514541P 2017-06-02 2017-06-02
PCT/US2018/035646 WO2018223023A1 (en) 2017-06-02 2018-06-01 Methods for treatment of fibrotic diseases

Publications (1)

Publication Number Publication Date
ES3055488T3 true ES3055488T3 (en) 2026-02-12

Family

ID=64456126

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18809912T Active ES3055488T3 (en) 2017-06-02 2018-06-01 Tegavivint for use in the treatment of pulmonary fibrosis

Country Status (6)

Country Link
US (3) US11298346B2 (https=)
EP (2) EP4656191A1 (https=)
JP (1) JP7159302B2 (https=)
CA (1) CA3065318A1 (https=)
ES (1) ES3055488T3 (https=)
WO (1) WO2018223023A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4656191A1 (en) * 2017-06-02 2025-12-03 Iterion Therapeutics, Inc. Methods for treatment of fibrotic diseases
WO2019099836A1 (en) * 2017-11-16 2019-05-23 Northwestern University Inhaled formulation of a molecular inhibitor of wnt/beta-catenin signaling for treating interstitial lung diseases
CN118105343A (zh) * 2018-06-01 2024-05-31 伊特里恩治疗有限公司 特加维因和相关化合物的制剂
EP4081209A4 (en) * 2019-12-24 2024-04-24 The Regents of the University of California Compositions and methods for treating cancer and improving epithelial homeostasis
WO2021207380A1 (en) * 2020-04-08 2021-10-14 The Trustees Of Indiana University Therapeutic strategies to manage facial contractures post injury
US11136307B1 (en) * 2020-09-29 2021-10-05 Iterion Therapeutics, Inc. Crystalline form of tegavivint, method of preparation, and use thereof
US11964054B2 (en) 2020-11-24 2024-04-23 Iterion Therapeutics, Inc. Formulations of tegavivint
US11571388B2 (en) 2020-11-24 2023-02-07 Iterion Therapeutics, Inc. Lyophilized formulations of tegavivint
CN119215047A (zh) * 2024-10-11 2024-12-31 浙江大学 一种芳香磺酰胺类化合物在制备防治肝损伤药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2152258B1 (en) 2007-05-10 2016-05-04 Avalon Pharmaceuticals Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
WO2010059142A1 (en) 2008-11-21 2010-05-27 Avalon Pharmaceuticals Anthraquinone dioximes and uses thereof
CA2782472C (en) * 2009-12-15 2019-04-16 The Hospital For Sick Children Method of treating scars and beta-catenin-mediated disorders
AU2012332111B2 (en) 2011-11-06 2016-11-17 Beta Cat Pharmaceuticals, Llc Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia
WO2013071232A1 (en) * 2011-11-11 2013-05-16 Beta Cat Pharmaceuticals, Llc Compositions and methods for inhibition of tbl-1 binding to disease-associated molecules
EP2968321A4 (en) * 2013-03-14 2016-11-09 Curegenix Inc COMPOUNDS FOR THE TREATMENT OF FIBROSIS DISEASES
EP3328819B1 (en) 2015-07-28 2020-04-01 Beta Cat Pharmaceuticals, Inc. Anthracene-9, 10-dione dioxime compounds prodrugs and their uses
KR102651136B1 (ko) * 2016-04-12 2024-03-25 삼성디스플레이 주식회사 유기 발광 표시 장치 및 그 제조 방법
EP4656191A1 (en) * 2017-06-02 2025-12-03 Iterion Therapeutics, Inc. Methods for treatment of fibrotic diseases
CN118105343A (zh) * 2018-06-01 2024-05-31 伊特里恩治疗有限公司 特加维因和相关化合物的制剂
US11571388B2 (en) * 2020-11-24 2023-02-07 Iterion Therapeutics, Inc. Lyophilized formulations of tegavivint

Also Published As

Publication number Publication date
EP3630101A1 (en) 2020-04-08
US20260102382A1 (en) 2026-04-16
US20230012615A1 (en) 2023-01-19
US20180344713A1 (en) 2018-12-06
EP3630101A4 (en) 2021-01-20
CA3065318A1 (en) 2018-12-06
JP2020522567A (ja) 2020-07-30
JP7159302B2 (ja) 2022-10-24
WO2018223023A1 (en) 2018-12-06
US11298346B2 (en) 2022-04-12
EP4656191A1 (en) 2025-12-03
EP3630101B1 (en) 2025-10-08

Similar Documents

Publication Publication Date Title
ES3055488T3 (en) Tegavivint for use in the treatment of pulmonary fibrosis
AU2018256605C1 (en) Benzoquinone Derivative E3330 in Combination with Chemotherapeutic Agents for the Treatment of Cancer and Angiogenesis
US10905701B2 (en) Compositions and methods for inhibiting arginase activity
CN102985085B (zh) 治疗双相型障碍的方法
ES2356093T3 (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y paracetamol.
KR20050042154A (ko) 통증의 치료에 사용하기 위한 알파-2-델타 리간드와 ｐｄｅｖ 억제제의 상승작용 조합물
JP2007536241A (ja) 糖尿病性腎症の処置のためのａ２ａアデノシンレセプターアゴニスト
AU2012255935A1 (en) Compounds for use in treatment of mucositis
WO2012158672A2 (en) Compounds for use in treatment of mucositis
CN106999540A (zh) 组合疗法
BR112020000827A2 (pt) métodos de tratamento de alterações de comportamento
US20220193053A1 (en) Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease
CN101321523A (zh) Cb1拮抗剂在治疗精神分裂症的阴性症状中的用途
ES2358931T3 (es) Uso de un inhibidor de quinasa p38 para el tratamiento de trastornos psiquiatricos.
ES2983998T3 (es) Compuesto de indol para tratar la cistitis intersticial
EP3706744B1 (en) Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use
JP2016029033A (ja) 組合せ物
EP3833354B1 (en) Tissue transglutaminase modulators for medicinal use
EP4469092A1 (en) Ntsr1-targeted radiopharmaceuticals and dna damage response inhibitor combination therapy
TW201806601A (zh) σ受體配體在皰疹後遺疼痛中的用途
CN115697316A (zh) 加巴喷丁和酮洛芬的协同掺加物、药物组合物及其医疗用途
BR122025008185A2 (pt) Usos terapêuticos de compostos de bifenil sulfonamida para a fabricação de um medicamento para tratar doenças ou transtornos renais em um indivíduo